Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) posted its earnings results on Thursday. The company reported C($0.18) earnings per share for the quarter, beating the consensus estimate of C($0.52) by C$0.34, reports.
Bradmer Pharmaceuticals Price Performance
Wall Street Analysts Forecast Growth
Separately, HC Wainwright raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 10th.
Check Out Our Latest Analysis on GLX
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Roth IRA Calculator: Calculate Your Potential Returns
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Overbought Stocks Explained: Should You Trade Them?
- MarketBeat Week in Review – 11/4 – 11/8
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
